ICU SeaStar Medical
- 5.2800
- +1.1600+28.16%
- 5.3999
- +0.1199+2.27%
SeaStar Medical News
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersMolecular Partners (NASDAQ:MOLN) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their outstanding shares is at $367.3 million. Zentalis Pharma (NASDAQ:ZNTL) s
Express News | SeaStar Medical Presents Selective Cytopheretic Device Featured At 42nd Vicenza Course AKI-CRT-ECOS And Critical Care Nephrology
SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
DENVER, June 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on
Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) fell sharply during Monday's session after the company announced its SBI-100 Ophthalmic Emulsion Phase 2a trial did not achieve target product profile and
Express News | Trading Halt: Halt Status Updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
SeaStar Medical: Jennifer Baird, Bernadette Vincent, John Neuman Appointed to Board >ICU
SeaStar Medical: Jennifer Baird, Bernadette Vincent, John Neuman Appointed to Board >ICU
Express News | SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
Trading Halt: Halted at 7:50:00 P.m. ET - Trading Halt: Halt News Pending
SeaStar Medical Announces The Publication Of A Peer-Reviewed Article In 'Nature Scientific Reports' Describes The Mechanism Of Action Of The Co's Selective Cytopheretic Device In The Immunomodulation Of Excessive Inflammation
SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces
SeaStar Medical To Carry Out 1-for-25 Reverse Stock Split On June 10th, 2024
June 7th - $SeaStar Medical(ICU.US)$ is about to implement a 1-for-25 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from June 10th, 2024.$SeaStar Medical(ICU.U
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of G-III Apparel Group, Ltd. (NASDAQ:GIII) fell sharply during Thursday's session after the company reported worse-than-expected quarterly sales results.G-III Apparel Group posted adjusted earn
Crude Oil Jumps 2%; Lululemon Posts Upbeat Earnings
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 50 points on Thursday.The Dow traded up 0.14% to 38,860.40 while the NASDAQ fell 0.07% to 17,175.73. The S&P 50
Express News | Seastar Medical Holding Shares Are Trading Lower After the Company Announced a 25-for-1 Reverse Stock Split
Express News | SeaStar Medical To Effect 25-For-1 Reverse Stock Split
Express News | SeaStar Medical Holding Corp Says Co's Common Stock Will Begin Trading on Split-Adjusted Basis Effective With Open of Market on June 10
SeaStar Medical: Shares to Begin Trading on Split-Adjusted Basis June 10 >ICU
SeaStar Medical: Shares to Begin Trading on Split-Adjusted Basis June 10 >ICU
Express News | SeaStar Medical Announces 25-for-1 Reverse Stock Split
Maxim Group Maintains SeaStar Medical(ICU.US) With Buy Rating, Maintains Target Price $2
Maxim Group analyst Anthony Vendetti maintains $SeaStar Medical(ICU.US)$ with a buy rating, and maintains the target price at $2.According to TipRanks data, the analyst has a success rate of 30.3% and
Express News | SeaStar MEdical Holdings Publishes Manuscript On Multiorgan Failure Patients Treated With Selective Cytopheretic Device
Analysis
Price Target
No Data
